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Abstract
The Wilms tumor gene (WT1) is mutated or deleted in patients with heredofamilial syndromes associated with
the development of Wilms tumors, but is infrequently mutated in sporadic Wilms tumors. By comparing the micro-
array profiles of syndromic versus sporadic Wilms tumors and WT1-inducible Saos-2 osteosarcoma cells, we iden-
tified interferon-inducible protein 16 (IFI16), a transcriptional modulator, as a differentially expressed gene and a
candidate WT1 target gene. WT1 induction in Saos-2 osteosarcoma cells led to strong induction of IFI16 expression
and its promoter activity was responsive to the WT1 protein. Immunohistochemical analysis showed that IFI16
andWT1 colocalized inWT1-repleteWilms tumors, but not in normal humanmidgestation fetal kidneys, suggesting
that the ability of WT1 to regulate IFI16 in tumors represented an aberrant pathologic relationship. In addition, en-
dogenous IFI16 and WT1 interacted in vivo in two Wilms tumor cell lines. Furthermore, IFI16 augmented the
transcriptional activity of WT1 on both synthetic and physiological promoters. Strikingly, short hairpin RNA
(shRNA)–mediated knockdown of either IFI16 or WT1 led to decreased growth of Wilms tumor cells. These data
suggest that IFI16 and WT1, in certain cellular context including sporadic Wilms tumors, may support cell survival.
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Introduction
Loss of functional mutations and deletion of WT1 occurs in ap-
proximately 10% of Wilms tumor cases. Most cases of Wilms tumor
are unilateral, sporadic, not associated with a malformation syndrome,
and express abundant levels of wild-type WT1 protein. This suggests
that WT1 is a tumor suppressor only in certain contexts. When re-
constituted into Wilms tumor cell lines devoid of wild-type WT1 as
well as a number of other cell lines including Saos cells, WT1 can slow
cell growth, induce cell cycle arrest, apoptosis, and initiate features of
epithelial differentiation [1–5]. However, the high level of expression
of WT1 in leukemia, as well as in a number of solid tumors, such as
breast cancer, lung cancer, primary thyroid cancer, and colorectal car-
cinoma, suggests that, in certain contexts, the protein is at least per-
missive for, if not stimulating, neoplastic cell growth [6]. Therefore,
the notion that WT1 functions as both a tumor suppressor and an
oncogene is widely supported (reviewed in Yang et al. [7]).
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IFI16 is a human member of hematopoietic interferon-inducible
nuclear proteins, can act as a transcriptional repressor, and affects the
transcriptional activity of other transcription factors [8–10]. Over-
expression of IFI16 in prostate and thyroid cancer cells inhibited cell
proliferation [11,12], whereas immortalized fibroblasts displayed de-
creased expression and promoter hypermethylation of IFI16, impli-
cating a role in cellular senescence and growth control as a tumor
suppressor [13]. In addition, decreased expression of IFI16 was ob-
served in breast cancer cell lines, suggesting that the loss of its expres-
sion contributes to cancer development [14].
In this study, we find that IFI16 is upregulated in Saos-2 cells onWT1
induction and is overexpressed in WT1-replete tumors. IFI16 forms a
complex with WT1 and augments its transcriptional activity. Most im-
portantly, loss of expression of IFI16 and WT1 inhibited the growth of
Wilms tumors, suggesting that both genes support cell survival.
Materials and Methods
Tumor and Control Tissues, and Northern Blot
Tumor and control tissue samples, and Northern blot analysis
were described previously [15].
Plasmids
Plasmids RSV-WT1A (−exon5/−KTS), RSV-WT1-F112Y, ZIF-
tk-Luc, and Sprouty1-Luc were described previously [16–18].
pCMV/SPORT6-IFI16B isoform (Clone ID: CS0DF005YG06)
was purchased from Invitrogen (Carlsbad, CA) and subcloned into
the pSP7, pCDNA3.1(+), or pRc/RSV vectors (Invitrogen). A
WT1A isoform cut out with Sau3A from pSP64-WT1A [2] was
cloned into BamHI-digested pBIG2i (gift from Dr. C. Strathdee).
Cell Culture and Transfection Methods
Saos-2–WT1A cells [3] were maintained in DMEM containing
10% FBS, 10 mM penicillin–streptomycin, 0.5 mg/ml G418, and
1 μg/ml of tetracycline. WT1A or a mutant WT1A-F112Y expres-
sion was induced by removing the tetracycline. 293 and 293T cells
were transfected using a transfection reagent (FuGENE 6; Roche
Diagnostics Corp., Indianapolis, IN). CCG99-11 cells isolated
from a sporadic Wilms tumor were cultured in DMEM, 10%
heat-inactivated FBS, 1 mM sodium pyruvate, and transfected using
a reagent (Lipofectamine Plus; Invitrogen). SK-NEP-1 cells (Ameri-
can Type Culture Collection, Manassas, VA) were maintained in
McCoy’s 5a medium (Invitrogen) with 10% FBS. Plasmid pBIG2i-
WT1A was transfected into CCG99-11 cells and stable clones were
selected with 400 μg/ml hygromycin (Invitrogen). Stable clones were
maintained in 50% of the drug concentration used for selection.
Microarray Analysis
Microarray data from Wilms tumor samples [15] were normal-
ized by the GeneChip Robust Multi-array Average algorithm and
re-analyzed using ArrayAssist Software 5.2.2 version (Stratagene, La
Jolla, CA). Significance analyses were performed by unpaired T-test
and asymptotic P-value computation. To generate the gene lists that
are differentially expressed between two groups, a P value cutoff of
< .005 and at least a two-fold change in either direction was applied.
Coimmunoprecipitation and Glutathione-S-Transferase
Fusion Protein Binding Assays
Cells were washed once in 1× PBS and lysed in ice-cold lysis buffer
containing 1% Triton X-100, 50 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 10 mM sodium pyrophosphate, 10 mM sodium fluoride,
10 mM EDTA, 1 mM sodium orthovanadate, 1 mM PMSF, and
one tablet of protease inhibitor (Complete; Roche) per 50 ml. After
5 minutes on ice, the lysates were centrifuged at 10,000g for 5 min-
utes at 4°C. Agarose-conjugated antibodies (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA) were added to 2 mg of lysates for
overnight incubation at 4°C. For glutathione-S-transferase (GST)
pull-down experiments, cell lysates (2 mg) were incubated for 3 hours
at 4°C with gentle rocking with the indicated GST–WT1 fusion pro-
teins immobilized on glutathione–Sepharose 4B beads (GE Health-
care, Piscataway, NJ). The beads were collected and washed three
times. The proteins were resolved by SDS-PAGE and transferred
to Immobilon-P PVDF membranes (Millipore, San Francisco, CA)
for immunoblot analysis.
Immunoblot Analysis
The following primary antibodies were used (all from Santa Cruz
Biotechnology): WT1 clone C19 rabbit polyclonal (1/1000); IFI16
clone 1G7 mouse monoclonal (1/1000); and GST clone Z5 rabbit poly-
clonal (1/1000). The GAPDHmouse monoclonal (1/20,000) was from
Chemicon International (Temecula, CA). For the detection, one of the
following conjugated antisera was used (GE Healthcare): peroxidase–
donkey anti-rabbit IgG (1/5000); peroxidase–sheep anti-mouse igG
(1/5000). The proteins were visualized using enhanced chemiluminis-
cence (GE Healthcare).
Reporter Gene Assays
The IFI16 promoter–reporter construct, containing DNA se-
quences between nt 231031 and 232710 of GenBank accession
AP002534, was cloned upstream of the firefly luciferase gene in
the pGL3-basic vector (Promega, Madison, WI). An artificial
WT1-responsive and Spry1 promoter reporter constructs were pre-
viously described [18]. Transient transfection was performed using
FuGENE 6 (Roche) in six-well plates. The Renilla luciferase plasmid
(Dual-Luciferase Reporter Assay System; Promega) was cotransfected
as an internal control and dual luciferase activities were measured af-
ter 48 hours.
Immunohistochemistry
Antigen retrieval for detection of IFI16 and WT1 was done
by boiling the deparaffinized sections on slides for 10 minutes in
1 mM EDTA (pH 8.0) in a microwave oven [15]. IFI16 clone
1G7 mouse monoclonal antibody, the WT1 clone 180 rabbit poly-
clonal antibody (Santa Cruz Biotechnology) and the secondary anti-
body (biotinylated horse anti-mouse and goat anti-rabbit; Vector
Laboratories, Burlingame, CA) were used at a dilution of 1:400.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as previ-
ously described [19] using the Chromatin Immunoprecipitation Kit
(Millipore) with the following specifications and modifications. Im-
munoprecipitation (IP) was carried out at 4°C using 5 μg of either
anti-WT1 (C19) or a polyclonal IgG per 1.5 × 107 cells per IP. After
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reversal of crosslinking, DNA was purified with a QIAquick Poly-
merase Chain Reaction (PCR) Cleanup Kit (Qiagen, Valencia, CA)
and eluted with 50 μl of elution buffer. DNA was quantitated by
real-time PCR. The PCR reaction contained 2 μl of either immuno-
precipitated sample or 10% of input DNA, and 0.4 μM of each
primer, 12.5 μl of 2× SYBR Green Mix (Qiagen) in 25 μl of reaction.
Primer sequences are the following:
IFI16-Promoter-F: 5′AGCCCTTGCCAGGAAACTGTTC,
IFI16-Promoter-R: 5′CCGCAGGATGTTGTAATCTCCAG
IFI16-Exon-F: 5′TTCCATAGAAGACAGTGCCCAGAG
IFI16-Exon-R: 5′CGGTCAGCATTCACATCAGCC
RNA Interference
WT1 small interfering RNA (siRNA) sequence (5′AACTTGT-
CAGCGAAAGTTC3′) and IFI16 siRNA sequence [8] were con-
verted into hairpin siRNA templates (http://bioinfo2.clontech.com/
rnaidesigner). The shRNA were constructed in RNAi-Ready pSIREN-
RetroQ vector (Clontech, Palo Alto, CA).
Cell Proliferation Assays and Cell Cycle Analysis
CCG99-11 cells seeded at 2.5 × 106 cells per 10-cm plates
24 hours before transfection were transfected with 5 μg of shRNA
using Lipofectamine Plus (Invitrogen). After puromycin selection
(0.4 μg /ml) for 4 days, starting at 1 day posttransfection, cells were
plated for either cell proliferation assays or cell cycle analysis. The
proliferation assay was performed with a CellTiter 96 AQueous
One Solution kit (Promega) with 5000 cells/well in a 96-well plate.
Cell cycle analysis was performed using a BrdU Flow Kit (BD Phar-
mingen, San Diego, CA), pulsing cells for 30 min with bromodeoxy-
uridine (BrdU). Total DNA content by 7-AAD and BrdU reactivity
were analyzed by flow cytometry.
Results
Comparison of Gene Expression Profiles in Saos-2–WT1 Cells
and Wilms Tumors
Our laboratory previously reported that WT1 induction in Saos-2
osteosarcoma cell line caused apoptosis through the Bak pathway,
suggesting an active role of WT1 in both differentiation and apopto-
sis during renal development [3]. To identify direct WT1 targets in a
genome-wide scale, we compared gene expression profiles from the
Saos model system to a Wilms tumor data set [15]. In Saos-2 cells,
total RNAwas isolated before and 18 hours after WT1 induction from
three independent sets of cells and 520 genes, including the Bak gene
with a 10-fold increase, were differentially expressed with a cutoff of
2-fold and P value of less than .005 (Table W1). The reanalysis of
Wilms tumor data (WT1-replete vs WT1-null tumors) using the
GeneChip Robust Multi-array Average normalization algorithm with
the same cutoff identified a set of 408 differentially expressed genes
Figure 1. IFI16 is identified as a WT1 target from microarray analysis. (A) Differentially expressed genes from Saos-2 cells and previous
Wilms tumor data set are shown in a Venn diagram. With at least two-fold change on WT1 induction with P < .005, 41 genes are
differentially expressed in both data sets. (B) The WT1 expression in Saos-2–WT1A cells was induced by drug removal. Total RNA
was isolated at the indicated time points and analyzed with the indicated cDNA probes. (C) The IFI16 promoter–luc construct
(100 ng) was transiently cotransfected into 293T cells with indicated expression constructs in six-well plates. Cells were transfected
in triplicate, harvested after 48 hours, and assayed for relative luciferase activity. Standard deviations are from triplicate determinations.
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similar to those previously reported (Table W2). By comparing these
two gene lists (Figure 1A), we observed that most differentially ex-
pressed genes were exclusive to the cell line or tumor data set with
about 10% (41 genes) shared between these two systems (Table 1).
Because WT1 induces apoptosis in Saos-2 cells whereas its expression
is tolerated and consistent with proliferation and survival of Wilms
tumors, this small overlap may not be surprising and is consistent with
a considerable difference in the function of WT1 in the two systems.
The overlap in gene sets may represent features of WT1 function com-
mon in the tumor and cell line model. Among these genes, 13 were
consistently upregulated and 8 were downregulated in the presence of
WT1, whereas additional 20 genes were regulated in response to WT1
but changed in the opposite direction compared to Wilms tumor data.
We prioritized consideration of the biology of genes either activated in
the presence of WT1 in both systems or repressed in both tumor sam-
ples and cell lines. Accordingly, the putative tumor suppressor IFI16, a
gene previously implicated in tumor development, was upregulated
on induction of WT1 in Saos-2 cells and was overexpressed in
WT1-replete tumors. Our previous study showed that IFI16 was dra-
matically decreased when cells explanted from a primarily WT1-replete
tumor were exposed to exogenous transforming growth factor-β2, a
known inducer of epithelial–mesenchymal transition. This suggested
that IFI16 might play an important role in the phenotype of sporadic
Wilms tumors [15].
IFI16 Is a WT1 Target Gene and Its Promoter Is
Responsive to WT1
We validated Saos-2 microarray expression data by Northern blot
analysis. Upon WT1 induction in Saos-2 cells, IFI16 mRNA was
upregulated with kinetics that closely followed the induction of
WT1 mRNA (Figure 1B). In cotransfection experiments, transient
overexpression of WT1 activated the IFI16 promoter activity in a dose
dependent manner, whereas a point mutant of WT1 (F112Y), defec-
tive for transcriptional activation, failed to significantly affect the pro-
moter activity (Figure 1C ). Therefore, WT1 can induce IFI16 gene
expression and the IFI16 promoter is responsive to the WT1 protein.
Aberrant Coexpression of WT1 and IFI16 in Sporadic
Wilms Tumors
We also examined IFI16 transcript levels in the 21 Wilms tumors
(11 sporadic and 10 syndromic) to validate the Wilms microarray
data (Figure 2A). Northern blot analysis of IFI16 levels indicated
that, on average, there was 20-fold more IFI16 in sporadic WT1-
expressing tumors than in syndromic WT1-null tumors. In addition,
we performed real-time PCR to validate WT1 and IFI16 expression
in the tumor specimens and added as Figure W1. Immunohisto-
chemistry revealed that nuclear IFI16 was widespread in the malig-
nant blastemal component of a sporadic Wilms tumor, whereas
no staining was detected in the malignant blastemal component or
stromal cells of a syndromic Wilms tumor (Figure 2B, I–II ). Serial
sections of a second case of sporadic Wilms tumor showed coexpres-
sion of WT1 and IFI16 in the nuclei of the malignant epithelial cells
of the tumor (Figure 2B, III–IV, bold arrows). Notably, focal absence
Table 1. Differentially Expressed Genes Identified by Microarray Analysis in Both Wilms Tumor
Sets and Saos-2–WT1A Cell Line.
Affymetrix Probe Set ID Gene Symbol FC in Saos-2 FC in Wilms Tumor
Genes activated by WT1A
1684_s_at WT1 165.0 12.7 1500_at*
34265_at SCG5 18.5 4.9
34818_at ETV5 13.0 2.6
35976_at CITED1 11.2 30.4
38488_s_at IL15 8.4 10.7
38223_at TBC1D8 5.5 3.5
32055_g_at CCNT2 5.5 2.7
529_at DUSP5 5.1 4.2
317_at LGMN 4.7 2.1
32317_s_at SULT1A 3.9 3.0
38871_at BCL10 3.4 2.8
1456_s_at IFI16 3.3 6.0
289_at STAT3 3.0 2.4
Genes repressed by WT1A
34531_at FLRT1 0.06 0.24
35977_at DKK1 0.19 0.11
1731_at PDGFRA 0.23 0.05
32588_s_at ZFP36L2 0.26 0.40
39545_at CDKN1C 0.31 0.14
32607_at BASP1 0.38 0.32
36452_at SYNPO 0.43 0.29
37005_at NBL1 0.45 0.26
Genes changed in an opposite direction
41193_at DUSP6 45.0 0.20
40091_at BCL6 16.5 0.31
36694_at KCNS3 9.4 0.27
37183_at GAD1 5.6 0.08
37701_at RGS2 5.2 0.24
35638_at RUNX1T1 4.2 0.14
41544_at PLK2 4.2 0.14
514_at CBLB 3.9 0.38
37951_at DLC1 3.9 0.13
36224_g_at SFPQ 3.3 0.32
39878_at PCDH9 3.2 0.02
36065_at LDB2 2.8 0.21
38653_at PMP22 2.6 0.43
213_at ROR1 2.4 0.06
41644_at SASH1 2.3 0.45
39054_at GSTM1/2/4 2.2 0.45 556_s_at*
1467_at EPS8 2.1 0.50
1970_s_at FGFR2 0.28 7.6
36427_at ANKRD40 0.29 2.9
36099_at SFRS1 0.42 2.6
*Probe set number from the Wilms tumor data set are shown if different. Probe sets for the same gene
with less fold changes (FCs) were not shown. Hypothetical genes were not included in this table.
Figure 2. IFI16 is a signature gene and coexpressed with WT1 in sporadic Wilms tumors. (A) Northern blot analysis of IFI16 mRNA in
sporadic versus syndromic Wilms tumors. The alternatively spliced IFI16 isoforms are visualized as a broad band. Scatter plot of relative
IFI16mRNA levels was determined by Phosphorimaging of Northern blots. A t-test (two-sided; unequal variance) indicates that the IFI16
levels in sporadic and syndromic Wilms tumors were significantly different. (B) Coexpression of nuclear IFI16 and WT1 proteins in spo-
radic Wilms tumor, but not in normal fetal kidney. (I) Sporadic, (II) syndromic (III, IV) serial sections of a second case of sporadic Wilms
tumors, (V, VI) immunostaining of IFI16 and WT1 proteins in serial sections of a normal midgestation human fetal kidney.MBl, malignant
blastemal component; MSt, malignant stromal cell; MEp, malignant epithelial cell; Gl, glomerulus; St, stroma and undifferentiated mes-
enchyme; CM, condensing mesenchyme adjacent to ureteric bud epithelium. The images in I to IV were taken with a ×20 objective; the
images in V and VI were taken with a ×10 objective.
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of IFI16 staining was accompanied by a lack of staining for WT1
(Figure 2B, III, thin arrows). To determine the relationship of
WT1 and IFI16 during kidney development, sections of human kid-
ney from the midgestational stage were immunostained for both pro-
teins. Remarkably, this revealed a nonoverlapping pattern of
expression of the two proteins: the distribution of IFI16 protein
was a near-negative image of the distribution of WT1 (Figure 2B,
V–VI ). Taken together, these two proteins are aberrantly coexpressed
in Wilms tumors, not in normal kidney.
WT1 and IFI16 Form a Complex in Wilms Tumor Cell Lines
Because WT1 and IFI16 colocalized in the Wilms tumors, we de-
termined whether IFI16 physically interacts with WT1 protein in two
Wilms tumor cell lysates CCG99-11 and SK-NEP-1 cells. Coim-
munoprecipitation experiments showed that endogenous WT1 and
IFI16 proteins specifically coimmunoprecipitated in these Wilms tu-
mor cells (Figure 3A). Both cell lines express a low level of WT1 and
an extremely high level of IFI16, such that WT1 could only be de-
tected in these cells by immunoprecipitation followed by immunoblot
(Figure 3A, left and right; first lane). In vitro binding assays using the
indicated purified GST–WT1 fusion proteins showed that all three
isoforms of endogenous IFI16 from sporadic Wilms tumor cell lines
bound to full-length GST–WT1 and a GST–WT1 fusion protein con-
taining the four zinc fingers but not to GSTalone (Figure 3, B and C ).
However, a fusion protein containing only the amino-terminal 182–
amino acid domain showed less avidity for IFI16. Hence, WT1 phys-
ically interacts with IFI16 in large part through its zinc finger domain.
IFI16 Augments WT1 Transcriptional Activity
To understand the functional significance of the interaction be-
tween WT1 and IFI16, WT1 and IFI16 were coexpressed in 293
cells along with an artificial WT1-responsive promoter or the Spry1
promoter which contains a natural WT1 binding site [18]. WT1
modestly activated both promoters. IFI16 alone had no effect on
Spry1 reporter or a modest effect on Zif reporter (Figure 4, A and
B). However, when IFI16 was coexpressed with WT1, the transcrip-
tional activity of these reporter genes was dramatically augmented.
Intriguingly, Western blot analysis showed that coexpression of in-
creasing amounts of IFI16 resulted in increased levels of WT1 pro-
tein in a dose-dependent manner, which correlated with our previous
findings that WT1 can activate promoters in a dose dependent man-
ner [20]. We also tested whether IFI16 could affect the endogenous
level of previously validated WT1 target genes, amphiregulin and
c-myc [21,22]. Overexpression of WT1 on its own led to a 3-fold
increase in amphiregulin transcription and IFI16 only a 1.5-fold in-
crease, whereas the combination led to over a 6-fold increase in am-
phiregulin expression (Figure 4C ). By contrast, the endogenous level
of a WT1 repression target, c-myc, was not affected by WT1 and
IFI16. Collectively, these data suggest that IFI16 can augment the
ability of WT1 to activate target genes. Overexpression of IFI16
Figure 3. WT1 interacts with IFI16 in Wilms tumor cells. (A) WT1 was coimmunoprecipitated from CCG99-11 and SK-NEP-1 cell lysates
using a monoclonal IFI16 antibody. A control IP was performed using mouse IgG. A reciprocal co-IP was performed using a polyclonal
WT1 antibody (C19) and rabbit IgG as a control. (B) A schematic illustration of GST–WT1 fusion constructs. (C) In vitro GST–pull-down
experiments using Wilms tumor cell lysates.
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only caused a minimal increase in the endogenous level of WT1 tran-
scripts and proteins (data not shown), although the exogenous WT1
protein level was significantly increased by IFI16 (Figure 4, A and B).
Therefore, whereas some of the ability of IFI16 to augment WT1
activity may be due to increasing WT1 protein accumulation,
IFI16 may be acting as a co-factor as well.
Loss of WT1 or IFI16 Expression Inhibits Cellular Growth
To investigate the biologic significance of IFI16 and WT1 in
Wilms tumor, we downregulated either IFI16 or WT1 transcripts
in the Wilms tumor CCG99-11 cell line by transfection with shRNA
vectors able to target all isoforms of the two proteins, obtaining 40%
to 50% and 50% decreases in the WT1 and IFI16 mRNA levels,
respectively; the protein levels are shown in Figure 5B. The yield
of viable Wilms tumor CCG99-11 cells was decreased when trans-
fected with WT1 or IFI16 shRNA compared to a negative control
shRNA (Figure 5A) and the growth rate of these cells was significant-
ly slowed (Figure 5B). Furthermore, depletion of either WT1 or
IFI16 in the Wilms tumor cells led a dramatic decrease in cell cycle
entry and an accumulation of cells in both G1 and/or G2/M phase of
the cell cycle. The sub-G1 population indicative of apoptosis was in-
creased in both WT1- and IFI16-depleted cells (Figure 5C ).
In addition, further induction of WT1 in the CCG99-11 cells did
not cause apoptosis and resulted in no significant difference in cell
growth. Interestingly, both Wilms tumor cell lines tolerate a high
Figure 4. WT1 transcriptional activity is augmented by IFI16. Either a (A) ZIF-tk-Luc or a (B) Spry1-Luc construct was cotransfected with
a fixed amount of a RSV–WT1 vector and increasing amount of a RSV–IFI16 construct into 293 cells in a six-well plate in triplicate.
At 48 hours posttransfection, cells were lysed for luciferase assay. Equal volumes of cell lysates were loaded on 10% SDS-PAGE gels
for Western blots. (C) Either empty CMV vector (2 μg), CMV–WT1A (1 μg), CMV–IFI16B (1 μg), or CMV–WT1A (1 μg) plus CMV–IFI16B
(1 μg) plasmids were transfected into 293 cells in 60-mm plates. In the CMV–WT1A and CMV–IFI16B transfections, 1 μg of empty CMV
vector plasmid was added to yield the same amount of total DNA. The endogenous mRNA levels of amphiregulin and c-myc were
measured by real-time PCR in triplicates and normalized by that of GAPDH at 48 hours posttransfection. The graph represents three
independent experiments.
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level of tumor suppressor IFI16 protein. In summary, both WT1 and
IFI16 support cell survival of Wilms tumor cells.
Discussion
It remains unclear how and why WT1, originally identified as
a tumor suppressor protein, is highly expressed in some tumors,
including sporadic Wilms tumors. To dissect the functional complex-
ity of WT1, many studies including microarray analysis have identi-
fied some bona fide WT1 targets [3,4,18,20–25].
In this study, we compare genes modulated by induction of WT1
in Saos-2 cells with genes differentially expressed in WT1-replete and
WT1-mutant tumors, and found several genes in common (Table 1).
This includes a recently identified Wilms tumor blastema marker,
CITED1 (CBP/p300-interacting transactivators with glutamic acid/
aspartic acid–rich C-terminal domain) gene, which was aberrantly ex-
pressed in the nuclear compartment of Wilms tumor blastema, but
predominantly in cytosolic compartment in the normal kidney devel-
opment [26]. This finding supports the notion that the heterologous
Figure 5. The knockdown of WT1 and IFI16 expression by shRNA induces apoptosis and cell cycle arrest. (A) CCG99-11 cells were
transfected with indicated shRNA. A negative control shRNA (a half hairpin luciferase siRNA) was provided by Clontech. Positively trans-
fected cells were selected with puromycin for 4 days and the selected cells were counted by Trypan blue exclusion. The average numb-
ers and standard deviations resulted from three independent experiments. (B) After puromycin selection, cells were plated for cell
proliferation assays and Western blot analyses. Day 1 indicated for both the cell proliferation and Western blot assays represents 6
days posttransfection. The graph represents three independent experiments. For Western blot, the membrane was cut for IFI16 (85–
95 kDa), WT1 (52 kDa), and GAPDH (35 kDa) blots. The batch of WT1 antibody (C19) used in this blot was not clean showing some
nonspecific bands. Figure W2 shows the typical knockdown of WT1 detected by a good WT1 antibody. (C) Puromycin-selected cells
were replated in 60-mm plates and were labeled with BrdU (10 μM) for 30 minutes after 2 days of replating. Total DNA was labeled with
7-AAD before flow cytometry analysis. Data represent three independent experiments.
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Saos-2 system can identify some genes relevant to Wilms tumor pa-
thology. Our study identifies a pathologic link between WT1 ex-
pression and tumorigenesis. WT1 induces IFI16 expression in
human osteosarcoma Saos-2 cells and the IFI16 promoter activity
is activated by WT1 expression. Specifically, we show that IFI16 is
a signature gene of sporadic Wilms tumor. WT1 and IFI16 are ex-
pressed in different tissue compartments during normal kidney devel-
opment, but are aberrantly coexpressed in Wilms tumors. These two
proteins physically interacted in two different Wilms tumor cell line
lysates. In addition, WT1 was recruited to the IFI16 promoter in
Wilms tumor CCG99-11 cells as measured by ChIP (Figure 6).
The endogenous expression level of WT1 in CCG99-11 cells was
too low to consistently detect enriched signal from ChIP samples us-
ing an anti-WT1 antibody. Therefore, we used a CCG99-11 cell line
engineered to express additional WT1 in an inducible manner. The
relative fold enrichment of IFI16 promoter region over input was in-
creased from 1.2- to 7.9-fold after WT1 induction, whereas a nega-
tive control of IFI16 coding region was not enriched. Surprisingly,
when WT1 expression is downregulated in CCG99-11 cells using
shRNA, neither the mRNA nor the protein level of IFI16 changed.
This could be due to either an incomplete knockdown of WT1 expres-
sion (although almost 80% of WT1 protein was downregulated; Fig-
ure 5B and Figure W2) or loss of a regulatory mechanism during
tumor development or cell line establishment. Furthermore, WT1
may not be the only transcription factor regulating IFI16. The inter-
feron effector signal transducer and activators of transcription protein 3
(STAT3) is upregulated in the presence of WT1 in both Wilms tu-
mors and Saos-2 cells (Table 1) and others showed that STAT3 is ac-
tivated in sporadic Wilms tumors [27]. In addition, Kim et al. [12]
showed that the leukemia inhibitory factor/Janus kinase/STAT3 path-
way induced IFI16 expression upon activation of Ras or Raf in human
medullary thyroid carcinoma cells. Thus, whereas WT1 expression
may have some role in the genesis of aberrant IFI16 expression in spo-
radic Wilms tumors, other signaling pathways likely have a role in
maintaining its expression.
The abnormal coexpression of WT1 and IFI16 does appear rele-
vant for the growth of Wilms tumors. We showed that depletion of
either protein in a Wilms tumor cell line inhibited cell growth. This
observation contrasts with a prior report of a IFI16 as a tumor sup-
pressor in breast cancer cell lines [14] and as a growth inhibitor in
thyroid cancer cells [12]. Our data suggest that the constitutive ex-
pression of WT1 may activate an aberrant set of pathways and con-
tribute to tumorigenesis. To support this idea, DAVID gene ontology
analysis (http://david.abcc.ncifcrf.gov) showed that genes upregu-
lated in WT1-replete Wilms tumors are significantly enriched for
cellular metabolism and DNA-replication, whereas the genes down-
regulated are significantly enriched in development and morphogen-
esis. This suggests a progrowth role for WT1 in Wilms tumors.
Indeed, prior studies reported that WT1 functions as a stimulator
of cell growth correlating with its overexpression in multiple forms
of cancer (reviewed in Yang et al. [7]). In contrast, the upregulated
genes by WT1 in Saos cells are mostly involved in the response to
stress and DNA damage. This gene set is consistent with the apopto-
tic phenotype we and others observed on WT1 induction in this sys-
tem [3,5] and with the observation that WT1 overexpression was
associated with G1 arrest and induction of p21 [1]. Hence, the Saos
system may, only to a limited extent, reflect the function of WT1 in
already established tumors and may be more relevant to the acute
role of WT1 in guiding kidney development.
Our data suggest that once a primordial kidney cells is transformed
into a Wilms tumor, WT1 is not simply irrelevant to the process but
may be co-opted into the oncogenic process. As depicted in Figure 7,
under normal conditions, WT1 and IFI16 localize in different com-
partments in the developing kidney and play an inhibitory role in
cellular proliferation. When aberrantly coexpressed in the case of spo-
radic Wilms tumors, WT1 and IFI16 can form a complex in a pos-
itive feedback mechanism, in which IFI16 acts as a cofactor to
augment the ability of WT1 to activate target genes and support cel-
lular growth. The identity of other targets of WT1 that support
growth remains to be determined.
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Table W1. Differentially Expressed genes Identified By Microarray Analysis in Saos-2–WTIA Cell Line.
Up-regulated Down-regulated
Probe Set ID Unigene Gene Symbol FC Probe Set ID Unigene Gene Symbol FC
35965_at HSPA6 1726.9 36799_at Hs.142912 FZD2 122.3
36711_at Hs.517617 MAFF 352.3 41816_at Hs.57973 CARD10 100.8
1478_at Hs.558348 ITK 210.5 40528_at Hs.445265 LHX2 43.1
1684_s_at Hs.591980 WT1 165.0 350_at Hs.463569 ZNF161 27.7
1916_s_at Hs.25647 FOS 136.8 40175_at Hs.591307 C3orf40 20.5
34566_at Hs.534305 CALCB 122.8 34531_at Hs.584876 FLRT1 17.8
36326_at Hs.46296 NHLH2 79.9 32105_f_at Hs.523045 CAMK2G 17.5
31856_at Hs.151641 LRRC32 78.9 41466_s_at Hs.591312 ZNF148 15.4
1575_at Hs.489033 ABCB1 64.7 36619_r_at Hs.504609 ID1 15.0
875_g_at Hs.303649 CCL2 61.4 36319_at Hs.484423 FOXF2 15.0
790_at Hs.2561 NGFB 60.4 36515_at Hs.5920 GNE 14.8
1321_s_at Hs.436298 EMP1 59.9 37136_at Hs.489448 APS 14.1
432_s_at Hs.74647 TRAC 59.7 32628_at Hs.463569 ZNF161 13.4
34898_at Hs.632601 AREG 58.6 2017_s_at Hs.523852 CCND1 12.0
37958_at Hs.8769 TMEM47 55.5 38537_at Hs.591910 TRIM32 11.0
41193_at Hs.298654 DUSP6 45.0 36970_at Hs.461647 KIAA0182 10.3
36062_at Hs.125474 LPXN 32.1 32137_at Hs.433445 JAG2 10.0
40218_at Hs.444924 CDS1 31.5 40332_at Hs.67896 OGFR 8.9
32616_at Hs.491767 LYN 31.2 35249_at Hs.567387 CCNE2 8.3
37863_at Hs.1395 EGR2 30.7 35464_at Hs.467304 IL11 8.3
41038_at Hs.587558 NCF2 29.4 38688_at Hs.632464 POGZ 8.3
36979_at Hs.419240 SLC2A3 28.2 38131_at Hs.146688 PTGES 8.1
1717_s_at Hs.127799 BIRC3 22.4 34725_at Hs.509447 GRLF1 8.1
40919_at Hs.514451 SSTR2 21.0 34428_at Hs.102308 KCNJ8 7.7
34265_at Hs.156540 SCG5 18.5 1729_at Hs.460996 TRADD 7.2
38546_at Hs.478673 IL1RAP 18.4 859_at Hs.154654 CYP1B1 7.2
35936_g_at Hs.439777 CHKB 18.0 33747_s_at RNU17D 6.8
32962_at Hs.19904 CTH 18.0 35732_at Hs.40094 LRRC42 6.6
39634_at Hs.29802 SLIT2 17.7 36860_at Hs.104661 C19orf7 6.6
768_at Hs.182971 KPNA5 17.4 1005_at Hs.171695 DUSP1 6.4
34931_at Hs.131683 CPEB3 17.1 34950_at Hs.530930 ZNF423 6.3
34342_s_at Hs.313 SPP1 16.9 39575_at Hs.25924 AJAP1 6.2
40091_at Hs.478588 BCL6 16.5 32725_at Hs.591054 BID 6.2
32967_at FAIM3 16.4 38980_at Hs.269775 MAP3K7IP2 6.0
996_at Hs.483635 FGF1 16.0 37042_at Hs.76873 HYAL2 5.7
32676_at Hs.293970 ALDH6A1 15.7 37410_at Hs.78354 SURF5 5.4
287_at Hs.460 ATF3 15.4 41708_at Hs.516617 SATB2 5.4
34059_at Hs.133107 PVT1 13.8 35977_at Hs.40499 DKK1 5.4
39550_at Hs.387995 GLT25D2 13.5 1018_at Hs.91985 WNT10B 5.4
34818_at Hs.43697 ETV5 13.0 38795_s_at Hs.89781 UBTF 5.2
33410_at Hs.133397 ITGA6 12.4 40585_at Hs.513578 ADCY7 5.1
37055_at Hs.22634 ETV1 11.5 1152_i_at Hs.172944 CGB /// LHB 5.1
34181_at Hs.207776 AGA 11.4 33754_at Hs.94367 TITF1 5.1
36808_at Hs.535276 PTPN22 11.4 39790_at Hs.506759 ATP2A2 5.0
35976_at Hs.40403 CITED1 11.2 36096_at Hs.368884 REEP1 5.0
36744_at Hs.591866 SPAG1 11.1 40328_at Hs.66744 TWIST1 5.0
570_at Hs.307905 RELB 11.0 39580_at Hs.533260 KIAA0649 4.9
36943_r_at Hs.444975 PLAGL1 10.9 38019_at Hs.474833 CSNK1E 4.8
38370_at Hs.517228 TIAM1 10.4 40171_at Hs.140720 FRAT2 4.8
669_s_at Hs.436061 IRF1 10.4 40325_at Hs.66196 NTHL1 4.8
34749_at Hs.24030 SLC31A2 10.1 34299_at Hs.517557 ZNF278 4.7
846_s_at Hs.485139 BAK1 10.0 37619_at Hs.480364 METAP1 4.7
1658_g_at Hs.506076 PTPRR 9.9 31731_at Hs.405046 CBX4 4.7
32141_at Hs.245044 PPM1E 9.9 1563_s_at Hs.279594 TNFRSF1A 4.6
36629_at Hs.522074 TSC22D3 9.7 34288_at Hs.471751 CMKOR1 4.6
595_at Hs.591338 TNFAIP3 9.6 39808_at Hs.108219 WNT11 4.6
31692_at Hs.405994 HSPA1A 9.6 40099_at Hs.568509 ARHGEF2 4.5
36694_at Hs.414489 KCNS3 9.4 34857_at Hs.529609 ATP13A3 4.4
40570_at Hs.370666 FOXO1A 9.0 1731_at Hs.74615 PDGFRA 4.4
33249_at Hs.163924 NR3C2 8.7 32800_at Hs.590886 RXRA 4.4
39420_at Hs.505777 DDIT3 8.7 40472_at Hs.352614 AGPAT7 4.4
38488_s_at Hs.168132 IL15 8.4 41490_at Hs.104123 PRPS2 4.3
36671_at Hs.489207 ASNS 8.1 32146_s_at Hs.183706 ADD1 4.2
34439_at Hs.281898 AIM2 7.9 33131_at Hs.592947 SOX4 4.2
37875_at Hs.632462 GPA33 7.6 39570_at Hs.522493 CAMSAP1 4.1
36767_at Hs.72912 CYP1A1 7.4 35374_at Hs.309403 CROCC 4.1
33705_at Hs.198072 PDE4B 7.4 37760_at Hs.128316 BAIAP2 4.1
40574_at Hs.445496 MAP3K9 7.4 32768_at Hs.525061 TDRD3 4.0
501_g_at Hs.152096 CYP2J2 7.3 39168_at ZBED1 4.0
41501_at Hs.201918 HIPK3 7.2 32588_s_at Hs.503093 ZFP36L2 3.9
Up-regulated Down-regulated
Probe Set ID Unigene Gene Symbol FC Probe Set ID Unigene Gene Symbol FC
38142_at Hs.590977 ZNF211 7.2 35334_at Hs.567381 GYG2 3.9
752_s_at Hs.515210 DNAJB1 7.1 37358_at Hs.164853 UBE2E1 3.9
36917_at Hs.200841 LAMA2 6.9 31874_at Hs.322852 GAS2L1 3.9
41640_at Hs.11923 YIPF1 6.7 41504_s_at Hs.592063 MAF 3.8
2015_s_at Hs.73105 PMS2 6.7 41087_at Hs.99348 DLX5 3.8
40354_at Hs.135554 HSPA4L 6.6 41483_s_at Hs.2780 JUND 3.8
37194_at Hs.367725 GATA2 6.5 32592_at Hs.558466 KIAA0323 3.8
1576_g_at Hs.489033 ABCB1 6.5 39638_at Hs.513305 TFAP4 3.7
38037_at Hs.799 HBEGF 6.4 38354_at Hs.517106 CEBPB 3.7
37926_at Hs.508234 KLF5 6.3 40333_at Hs.68879 BMP4 3.7
41658_at Hs.343380 CDC42EP2 6.2 1781_at Hs.181128 ELK1 3.7
36634_at Hs.519162 BTG2 6.2 34355_at Hs.200716 MECP2 3.6
40016_g_at Hs.133539 MAST4 6.2 34803_at Hs.42400 USP12 3.6
41734_at Hs.571398 DENND3 6.1 32219_at Hs.470586 TLK1 3.6
40095_at Hs.155097 CA2 6.0 32963_s_at Hs.485938 RRAGD 3.6
31897_at Hs.104672 DOC1 6.0 1487_at Hs.110849 ESRRA 3.6
35718_at Hs.145150 SP110 6.0 34292_at Hs.23119 CXorf12 3.6
33323_r_at Hs.523718 SFN 5.7 1970_s_at Hs.533683 FGFR2 3.6
41373_s_at Hs.584777 MAP1B 5.7 32985_at Hs.135787 SALL1 3.5
31508_at Hs.533977 TXNIP 5.7 40677_at Hs.82482 CCDC106 3.5
37944_at Hs.86724 GCH1 5.6 32107_at Hs.473894 C21orf25 3.5
37183_at Hs.420036 GAD1 5.6 35318_at Hs.5737 FAM20B 3.5
38223_at Hs.442657 TBC1D8 5.5 36615_at Hs.436446 ARMET 3.5
32055_g_at Hs.591241 CCNT2 5.5 41448_at Hs.592166 HOXA10 3.4
32901_s_at Hs.7879 IFRD1 5.4 34268_at Hs.422336 RGS19 3.4
1606_at Hs.371218 EPHA4 5.3 39829_at Hs.631897 ARL4C 3.4
41409_at Hs.10649 C1orf38 5.3 39710_at Hs.36053 C5orf13 3.4
40395_at Hs.497626 PLXNA2 5.3 36427_at Hs.463426 ANKRD40 3.4
39671_at Hs.584880 DNM3 5.2 39253_s_at Hs.6906 RALA 3.4
624_at Hs.123072 RAB3B 5.2 40604_at Hs.173135 DYRK2 3.4
37701_at Hs.78944 RGS2 5.2 31823_at Hs.191482 CUTL1 3.3
40855_at Hs.98259 SAMD4A 5.2 37159_at Hs.469280 AHDC1 3.3
32193_at Hs.584845 PLXNC1 5.2 39545_at Hs.106070 CDKN1C 3.2
34427_g_at Hs.101840 MR1 5.2 39035_at Hs.591856 EDD1 3.2
35870_at Hs.156738 AASS 5.1 38429_at Hs.83190 FASN 3.2
37028_at Hs.631593 PPP1R15A 5.1 39108_at Hs.592160 LSS 3.2
39215_at Hs.219140 NPPB 5.1 1848_at Hs.190334 RAP1A 3.1
529_at Hs.2128 DUSP5 5.1 41475_at Hs.494457 NINJ1 3.1
36632_at Hs.462457 AKAP10 4.9 38988_at Hs.113876 WHSC1 3.1
40391_at Hs.310591 SLC22A4 4.8 41573_at Hs.531587 SP3 3.0
35604_at Hs.517897 ENDOGL1 4.7 1347_at Hs.153752 CDC25B 3.0
317_at Hs.18069 LGMN 4.7 33776_at Hs.547236 RWDD3 3.0
38163_at Hs.117767 RIMS2 4.6 36487_at Hs.55967 SHOX2 3.0
35341_at Hs.584851 TRIM38 4.6 32209_at Hs.25723 FAM89B 3.0
34759_at Hs.519469 SLC30A1 4.6 40446_at Hs.166204 PHF1 3.0
35497_at Hs.310458 TSPAN2 4.5 34180_at Hs.98594 ARHGEF10 3.0
41123_s_at Hs.190977 ENPP2 4.4 35848_at Hs.193118 RAI17 3.0
1832_at Hs.593171 MCC 4.4 35230_at Hs.29344 TICAM1 3.0
35228_at Hs.439777 CPT1B 4.3 38772_at Hs.8867 CYR61 3.0
37099_at Hs.507658 ALOX5AP 4.3 32192_g_at Hs.371617 PCGF2 3.0
34335_at Hs.149239 EFNB2 4.3 34657_at Hs.105105 AKAP11 3.0
39945_at Hs.516493 FAP 4.3 35186_at Hs.270621 TAF5L 2.9
31808_at Hs.489811 ING3 4.3 34256_at Hs.415117 ST3GAL5 2.9
41048_at Hs.96 PMAIP1 4.2 37985_at Hs.89497 LMNB1 2.9
35008_at Hs.58756 PER2 4.2 39812_at Hs.109059 MRPL12 2.9
39797_at Hs.529925 UBR2 4.2 36508_at Hs.58367 GPC4 2.9
36454_at Hs.210995 CA12 4.2 38279_at Hs.584760 GNAZ 2.9
35638_at Hs.368431 RUNX1T1 4.2 1373_at Hs.371282 TCF3 2.9
33803_at Hs.2030 THBD 4.2 38010_at Hs.144873 BNIP3 2.9
41389_s_at Hs.104119 RAGE 4.2 37113_at Hs.446350 TGFBRAP1 2.8
40408_at Hs.274873 CARS 4.2 41460_at RBM14 2.8
41544_at Hs.398157 PLK2 4.2 33402_at Hs.592190 KDELR3 2.8
1370_at Hs.591742 IL7R 4.2 1637_at Hs.234521 MAPKAPK3 2.8
40310_at Hs.519033 TLR2 4.1 32587_at Hs.503093 ZFP36L2 2.8
1038_s_at Hs.520414 IFNGR1 4.1 38122_at Hs.516866 SLC23A2 2.7
35408_i_at Hs.296731 ZNF44 4.1 37266_at Hs.522885 ZNF32 2.7
36312_at Hs.368077 SERPINB8 4.0 32696_at Hs.428027 PBX3 2.7
40755_at Hs.549053 MICA 4.0 266_s_at Hs.632285 CD24 2.7
37163_at Hs.23361 ABTB2 4.0 39059_at Hs.503134 DHCR7 2.7
173_at Hs.317632 CDH18 3.9 41308_at Hs.208597 CTBP1 2.7
Table W1. (continued )
Up-regulated Down-regulated
Probe Set ID Unigene Gene Symbol FC Probe Set ID Unigene Gene Symbol FC
40285_at Hs.497867 NVL 3.9 31788_at Hs.475208 ZBED4 2.7
39963_at Hs.44720 ZNF307 3.9 41463_at Hs.112023 FLJ38984 2.7
40607_at Hs.173381 DPYSL2 3.9 39866_at Hs.462492 USP22 2.7
37825_at Hs.122006 GALK2 3.9 38338_at Hs.515536 RRAS 2.6
37599_at Hs.406238 AOX1 3.9 32610_at Hs.424312 PDLIM4 2.6
514_at Hs.430589 CBLB 3.9 36142_at Hs.434961 ATXN1 2.6
40516_at Hs.171189 AHR 3.9 35363_at Hs.528305 DDX17 2.6
883_s_at Hs.81170 PIM1 3.9 32607_at Hs.201641 BASP1 2.6
32317_s_at Hs.546304 SULT1A2 3.9 40780_at Hs.501345 CTBP2 2.6
37951_at Hs.134296 DLC1 3.9 34261_at Hs.585089 PCYT2 2.6
39411_at Hs.12813 TIPARP 3.8 32057_at Hs.567412 LRRC17 2.6
35488_at Hs.179312 SNAPC1 3.8 38108_at Hs.332138 PPT2 2.6
36548_at Hs.6224 KIAA0895 3.7 38738_at Hs.474005 SUMO3 2.5
33955_at Hs.673 IL12A 3.7 38084_at Hs.381189 CBX3 2.5
39544_at Hs.207106 DMN 3.7 851_s_at Hs.471508 IRS1 2.5
34311_at Hs.28988 GLRX 3.7 41083_at Hs.99093 C19orf37 2.5
1911_s_at Hs.80409 GADD45A 3.7 39182_at Hs.9999 EMP3 2.5
38148_at Hs.151573 CRY1 3.7 36932_at Hs.75782 GTF3C2 2.5
37801_at Hs.201939 ATP6V0A2 3.7 1603_g_at Hs.478199 PRKCI 2.5
32084_at Hs.443572 SLC22A5 3.6 41649_at Hs.120844 FOXJ2 2.5
1944_f_at Hs.195364 MLH1 3.6 39748_at Hs.14846 SLC7A1 2.5
35588_at Hs.546637 HIT-40 3.6 37034_at Hs.458747 ANP32A 2.5
39297_at Hs.584776 MAB21L1 3.6 40078_at Hs.25338 PRSS23 2.5
34269_at Hs.468688 C10orf137 3.6 33221_at Hs.443881 PAXIP1 2.5
37960_at Hs.8786 CHST2 3.5 33576_at Hs.591208 SLITRK5 2.4
38164_at Hs.61438 RPGR 3.4 36532_at Hs.434494 SYNJ2 2.4
37833_at Hs.532635 SERPINA6 3.4 36099_at Hs.68714 SFRS1 2.4
33364_at Hs.584841 PDE4DIP 3.4 36612_at Hs.632129 KIAA0280 2.4
39219_at Hs.429666 CEBPG 3.4 35378_at Hs.154704 LHB 2.4
1099_s_at Hs.1581 GSTT2 3.4 40405_at Hs.159223 NAB2 2.3
40852_at Hs.193842 TDRD7 3.4 41116_at Hs.134846 MGC24381 2.3
38871_at Hs.193516 BCL10 3.4 38652_at Hs.500897 C10orf26 2.3
34987_s_at Hs.444314 HNRPA1 3.4 1551_g_at Hs.513230 MRPL28 2.3
32624_at Hs.113150 GARNL1 3.4 34675_at STON1 2.3
38105_at Hs.432996 FLJ11021 3.4 38286_at Hs.528051 AMOT 2.3
806_at Hs.632415 PLK3 3.3 902_at Hs.523329 EPHB2 2.3
38878_at Hs.485717 SMAP1 3.3 35839_at Hs.71465 SQLE 2.3
33165_at Hs.525091 TOE1 3.3 33889_s_at Hs.517357 DGCR2 2.3
35372_r_at Hs.624 IL8 3.3 36452_at Hs.435228 SYNPO 2.3
37819_at Hs.591036 MDM1 3.3 38125_at Hs.414795 SERPINE1 2.3
37539_at Hs.497148 RGL1 3.3 37005_at Hs.632384 NBL1 2.2
32965_f_at Hs.274402 HSPA1B 3.3 41106_at Hs.10082 KCNN4 2.2
40308_at Hs.467862 KIAA1240 3.3 1497_at Hs.1116 LTBR 2.2
1456_s_at IFI16 3.3 40695_at Hs.534808 IMPDH1 2.2
36224_g_at Hs.355934 SFPQ 3.3 1396_at Hs.369982 IGFBP5 2.2
224_at Hs.435001 KLF10 3.3 40049_at Hs.380277 DAPK1 2.2
36139_at Hs.571184 TRAF3IP2 3.2 35755_at Hs.308122 ITPK1 2.2
39878_at Hs.407643 PCDH9 3.2 41140_at Hs.517240 IFNGR2 2.2
39585_at Hs.522274 CCRK 3.2 39865_at Hs.546627 KCTD7 2.2
802_at Hs.530251 TAF12 3.2 34433_at Hs.103854 DOK1 2.1
37579_at Hs.519702 CYFIP2 3.2 32735_at Hs.531564 PHLPPL 2.1
32716_at Hs.524488 DGKA 3.2 39247_at Hs.442182 ABCC6 2.1
32804_at Hs.439480 RBM5 3.1 35322_at Hs.465870 KEAP1 2.1
41706_at Hs.508343 AMACR 3.1 37978_at Hs.513484 QPRT 2.1
587_at Hs.154210 EDG1 3.1 159_at Hs.435215 VEGFC 2.1
40455_at Hs.167115 ENDOD1 3.1 34778_at Hs.288467 LRRC15 2.1
34279_at Hs.515947 NBPF14 3.1 32238_at Hs.193163 BIN1 2.1
32970_f_at Hs.494567 HABP4 3.1 39341_at Hs.534360 TRIP6 2.1
40381_at Hs.75264 ZNF510 3.1 35714_at Hs.284491 PDXK 2.1
289_at Hs.463059 STAT3 3.0 36641_at Hs.446123 CAPZA2 2.1
38390_at Hs.211800 COG2 3.0 40840_at Hs.381072 PPIF 2.1
38345_at Hs.246344 CEP110 3.0 41725_at Hs.129332 CSNK1G2 2.1
32134_at Hs.592286 TES 3.0 38030_at Hs.529577 SR140 2.1
892_at Hs.351316 TM4SF1 2.9 37890_at Hs.446414 CD47 2.1
39641_at Hs.3041 UNG2 2.9 38631_at Hs.525607 TNFAIP2 2.1
1846_at Hs.4082 LGALS8 2.9 39876_at Hs.631503 ENTPD6 2.1
36024_at PRR4 2.9 39117_at Hs.211441 PHF2 2.0
1969_s_at Hs.184298 CDK7 2.9 35816_at Hs.695 CSTB 2.0
38525_at Hs.17200 STAM2 2.9 37334_at Hs.96996 HNRPA0 2.0
450_g_at Hs.59106 CGRRF1 2.9
Table W1. (continued )
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Up-regulated Down-regulated
Probe Set ID Unigene Gene Symbol FC Probe Set ID Unigene Gene Symbol FC
36065_at Hs.23748 LDB2 2.8
32066_g_at Hs.200250 CREM 2.8
33220_at Hs.157883 ZNF187 2.8
31790_at Hs.507704 STARD13 2.8
31914_at Hs.191164 CHD1L 2.8
40869_at Hs.188879 RBM6 2.8
40602_at Hs.59332 SPRED2 2.8
32660_at Hs.170999 LBA1 2.7
40798_s_at Hs.578508 ADAM10 2.7
41126_at Hs.323878 SLC1A4 2.6
36901_at Hs.267632 TMF1 2.6
34200_at Hs.193043 CLCN6 2.6
1959_at Hs.459106 AZIN1 2.6
38653_at Hs.372031 PMP22 2.6
38276_at Hs.458276 NFKBIE 2.6
33753_at Hs.574538 DAAM1 2.6
38498_at Hs.373074 CRYBB2 2.6
33263_at Hs.369762 ENOSF1 2.6
34285_at Hs.517946 KLHL18 2.6
32132_at Hs.409210 DZIP3 2.5
32718_at Hs.421194 TPST1 2.5
36933_at Hs.372914 NDRG1 2.5
160030_at Hs.125180 GHR 2.5
37032_at Hs.503911 NNMT 2.5
41356_at Hs.370549 BCL11A 2.5
41235_at Hs.496487 ATF4 2.5
948_s_at Hs.581725 PPID 2.5
37222_at Hs.268573 GSTT1 2.5
36003_at Hs.253197 PARN 2.5
40766_at Hs.534847 C4A /// C4B 2.5
40591_at Hs.463295 CDC27 2.4
36097_at Hs.501629 IER2 2.4
41103_at Hs.1004 BRPF1 2.4
1258_s_at Hs.567265 ERCC4 2.4
581_at Hs.489646 LAMB1 2.4
39827_at Hs.523012 DDIT4 2.4
35831_at Hs.592144 ATP9A 2.4
213_at Hs.128753 ROR1 2.4
32657_at Hs.518197 IQCB1 2.4
35166_at Hs.369488 DSCR3 2.4
34457_at Hs.467981 SLC30A3 2.4
1491_at Hs.591286 PTX3 2.4
33774_at Hs.591630 CASP8 2.4
1209_at Hs.591983 TRAF6 2.4
37184_at STX1A 2.4
34777_at Hs.441047 ADM 2.3
34280_at Hs.22785 GABRE 2.3
33228_g_at Hs.512211 IL10RB 2.3
479_at Hs.481980 DAB2 2.3
35628_at Hs.31130 TM7SF2 2.3
35813_at Hs.193613 TNPO3 2.3
39822_s_at Hs.110571 GADD45B 2.3
32673_at Hs.159028 BTN2A1 2.3
37537_at Hs.792 TRIM23 2.3
670_s_at Hs.437075 CREB5 2.3
35253_at Hs.429434 GAB2 2.3
41644_at Hs.193133 SASH1 2.3
2064_g_at Hs.258429 ERCC5 2.3
943_at Hs.149261 RUNX1 2.3
37646_at Hs.82502 POLD3 2.3
1480_at Hs.90093 HSPA4 2.3
646_s_at Hs.73986 CLK2 2.3
36243_at Hs.575090 TLR1 2.3
38129_at Hs.599462 GK 2.2
39054_at Hs.279837 GSTM1/2/4 2.2
31896_at Hs.467759 NAG 2.2
34386_at MBD4 2.2
39370_at Hs.356061 MAP1LC3B 2.2
38962_at Hs.130836 TRIM66 2.2
36371_at MFAP3 2.2
Table W1. (continued )
Up-regulated Down-regulated
Probe Set ID Unigene Gene Symbol FC Probe Set ID Unigene Gene Symbol FC
40153_at Hs.352018 TAP1 2.2
34492_at SFT2D2 2.2
41233_at Hs.490745 DNAJB6 2.1
35937_at Hs.211580 MICB 2.1
1584_at Hs.656 CDC25C 2.1
39429_at Hs.202470 UVRAG 2.1
1325_at Hs.519005 SMAD1 2.1
40072_at Hs.154655 MRPS31 2.1
32222_at Hs.513470 NFATC2IP 2.1
35165_at Hs.107845 CCDC93 2.1
39114_at Hs.93675 C10orf10 2.1
38029_at Hs.502769 SLC3A2 2.1
1495_at Hs.49787 LTBP1 2.1
41780_at Hs.530749 PPFIA1 2.1
32824_at Hs.523454 TPP1 2.1
1467_at Hs.591160 EPS8 2.1
167_at Hs.433702 EIF5 2.0
36890_at Hs.192233 PPL 2.0
41346_at Hs.474667 LARGE 2.0
38393_at Hs.440025 KIAA0247 2.0
36989_at Hs.76111 DAG1 2.0
39267_at Hs.598312 PGM3 2.0
Note: Hypothetical genes are not listed.
Table W2. Differentially Expressed genes Identified By Microarray Analysis in Wilms Tumor Sets.
Probe Set ID Gene Symbol FC Regulation Probe Set ID Gene Symbol FC Regulation
34083_at 15E1.2 2.1 up 35162_s_at ACVR2A 2.4 down
38434_at AAMP 5.2 up 35985_at AKAP2 /// PALM2-AKAP2 3.6 down
38830_at ABCF3 2.9 up 32805_at AKR1C1 /// AKR1C2 4.2 down
134_at ABI2 3.7 up 37015_at ALDH1A1 8.8 down
36448_at ABI2 7.0 up 1929_at ANGPT1 2.4 down
33888_at ACTR1B 2.1 up 39315_at ANGPT1 3.5 down
36269_at ADAMTS3 2.5 up 31444_s_at ANXA2 /// ANXA2P1 /// ANXA2P3 2.3 down
36427_at ANKRD40 2.9 up 769_s_at ANXA2 /// ANXA2P1 /// ANXA2P3 2.3 down
33944_at APLP2 3.3 up 32607_at BASP1 3.1 down
41764_at APOC1 4.1 up 40091_at BCL6 3.2 down
38149_at ARHGAP25 3.6 up 38126_at BGN /// TSHZ1 3.5 down
1984_s_at ARHGDIB 5.3 up 1113_at BMP2 3.0 down
39043_at ARPC1B /// LOC653888 2.4 up 40367_at BMP2 2.2 down
35810_at ARPC3 2.7 up 34303_at C10orf56 2.5 down
34691_f_at ARPC4 3.3 up 41013_at C10orf72 3.2 down
40439_at ASNA1 5.3 up 41533_at C8orf72 3.2 down
38684_at ATP2C1 2.4 up 40475_at CAPN6 5.1 down
40096_at ATP5A1 4.1 up 35632_at CBLB 2.1 down
40134_at ATP5J2 2.4 up 36707_s_at CDKL5 3.5 down
34890_at ATP6V1A 8.4 up 1787_at CDKN1C 7.4 down
39432_at B4GALT4 2.2 up 38673_s_at CDKN1C 5.4 down
2065_s_at BAX 6.1 up 39545_at CDKN1C 6.6 down
2067_f_at BAX 3.6 up 32249_at CFH /// CFHR1 4.8 down
36812_at BCAR3 4.2 up 41000_at CHES1 2.4 down
38871_at BCL10 2.8 up 35168_f_at COL16A1 9.3 down
33434_at BET1 2.0 up 38420_at COL5A2 4.9 down
394_at BLMH 5.3 up 36455_at COL9A3 5.1 down
39133_at BLOC1S1 4.2 up 36606_at CPE 2.8 down
39077_at C17orf45 5.4 up 39842_at CRLF1 12.6 down
33403_at C1orf77 2.3 up 38111_at CSPG2 9.0 down
35001_at C6orf69 2.9 up 38112_g_at CSPG2 8.4 down
40132_g_at C7orf28A /// C7orf28B 2.7 up 40782_at DHRS3 2.3 down
41207_at C9orf3 3.0 up 36552_at DKFZP586P0123 2.2 down
32055_g_at CCNT2 2.7 up 35977_at DKK1 9.2 down
38567_at CD1D 9.4 up 37951_at DLC1 2.9 down
39389_at CD9 4.1 up 34712_at DNMBP 2.5 down
1527_s_at CG018 2.7 up 38057_at DPT 2.1 down
34240_s_at CG018 2.7 up 41193_at DUSP6 2.3 down
40980_at CHD8 22.3 up 160040_at EDN3 3.8 down
35976_at CITED1 30.4 up 37865_at EDN3 4.5 down
Probe Set ID Gene Symbol FC Regulation Probe Set ID Gene Symbol FC Regulation
34194_at CLIC5 /// LOC653816 4.0 up 1507_s_at EDNRA 9.4 down
41423_at CLSTN3 2.2 up 40380_at ELAVL4 2.4 down
32366_at CNTFR 4.2 up 39098_at ELN 2.0 down
35385_at COQ7 2.0 up 35740_at EMILIN1 6.0 down
37248_at CPZ 7.7 up 1467_at EPS8 2.0 down
1057_at CRABP2 5.7 up 31843_at ESRRG 4.2 down
38219_at CRK 2.1 up 35226_at EYA2 8.0 down
40272_at CRMP1 9.7 up 40454_at FAT 2.1 down
39724_s_at CUL1 2.1 up 38012_at FBN2 6.9 down
34339_at CYB5B 3.8 up 32224_at FCHSD2 2.0 down
38413_at DAD1 2.6 up 1616_at FGF9 16.9 down
1754_at DAXX 3.0 up 34531_at FLRT1 4.1 down
40292_at DBC1 3.1 up 34853_at FLRT2 7.3 down
36158_at DCTN1 10.1 up 38356_at FST 16.7 down
1243_at DDB2 4.4 up 37183_at GAD1 12.4 down
33650_at DDX27 2.3 up 31497_at GAGE1 /// GAGE2 /// GAGE8 ///
LOC645037 /// LOC645093 2.2 down
826_at DDX3X 2.7 up 37714_at GAP43 22.3 down
41201_at DNM1L 2.1 up 39482_at GAPDH 4.7 down
35679_s_at DPP6 4.3 up 37829_at GAS2 6.9 down
529_at DUSP5 4.2 up 39665_at GLRB 7.6 down
1703_g_at E2F4 5.1 up 35071_s_at GMDS 2.9 down
188_at EFNB1 2.1 up 556_s_at GSTM1 /// GSTM2 /// GSTM4 2.2 down
2076_s_at EFNB1 2.6 up 39704_s_at HMGA1 3.2 down
39721_at EFNB1 2.4 up 160042_s_at HOXB6 4.4 down
31845_at ELF4 2.6 up 37618_at HOXB7 2.9 down
40302_at EMID1 4.5 up 37558_at IGF2BP3 16.3 down
39631_at EMP2 2.1 up 38086_at IGSF3 5.2 down
39542_at ENC1 2.8 up 35472_at KCNJ15 14.0 down
39010_at ENSA 2.1 up 41325_at KCNK3 2.6 down
39011_at ENSA 5.4 up 36694_at KCNS3 3.7 down
39012_g_at ENSA 5.3 up 38972_at KCTD12 4.1 down
40514_at ERGIC3 6.5 up 41458_at KIAA0467 2.3 down
34818_at ETV5 2.6 up 32110_at KIAA0523 6.2 down
37073_at EYA1 2.8 up 39615_at KIAA1026 5.9 down
36876_at FAH 3.1 up 36065_at LDB2 4.8 down
38424_at FAM62A 2.3 up 41073_at LGR5 23.4 down
1440_s_at FAS 2.3 up 35998_at LOC284244 2.8 down
40336_at FDXR 2.5 up 36811_at LOXL1 3.0 down
1363_at FGFR2 3.5 up 33359_at LPHN3 6.4 down
1970_s_at FGFR2 7.6 up 34800_at LRIG1 2.4 down
34354_at FGFR2 2.8 up 35917_at MAP1A 3.6 down
1772_s_at FNTA 2.0 up 40398_s_at MEOX2 78.4 down
37488_at FNTB 3.0 up 40399_r_at MEOX2 26.8 down
38336_at FRMD4B 2.3 up 35961_at MGAT5 11.0 down
34716_at FUSIP1 /// LOC642558 3.6 up 34296_at MID1 12.7 down
34717_s_at FUSIP1 /// LOC642558 /// LOC653884 2.5 up 35975_at MLLT3 3.7 down
32109_at FXYD1 4.2 up 36834_at MOXD1 6.4 down
34472_at FZD6 5.9 up 38013_at MTUS1 3.7 down
777_at GDI2 3.4 up 36861_at MXRA5 3.3 down
37904_s_at GNL1 3.5 up 1973_s_at MYC 7.4 down
36262_at GNS 4.7 up 37724_at MYC 5.1 down
1834_at GPR176 8.5 up 39777_at MYCBP2 2.0 down
38966_at GPSN2 3.5 up 33235_at NAV3 16.4 down
33855_at GRB2 2.6 up 37005_at NBL1 3.8 down
466_at GTF2I /// GTF2IP1 /// LOC649791 2.3 up 38803_at NCALD 3.1 down
35396_at HAS2 7.1 up 34873_at NEBL 4.5 down
476_s_at HDAC1 4.9 up 32512_at NEF3 26.5 down
38779_r_at HDGF 2.4 up 34234_f_at NKTR 2.7 down
37383_f_at HLA-B /// HLA-C 3.7 up 40344_at NLGN1 2.1 down
36773_f_at HLA-DQB1 5.3 up 36695_at OLFML1 2.2 down
36878_f_at HLA-DQB1 5.4 up 41191_at PALLD 2.6 down
41723_s_at HLA-DRB1 /// HLA-DRB3 /// HLA-DRB4 /// HLA-DRB6 ///
LOC649143 /// LOC651845 /// LOC652479
7.9 up 37154_at PCDH17 7.0 down
37421_f_at HLA-F 3.5 up 39878_at PCDH9 47.4 down
40369_f_at HLA-G 4.0 up 31609_s_at PCOLCE 7.2 down
40370_f_at HLA-G 3.6 up 1731_at PDGFRA 18.9 down
35737_at HMGN4 2.6 up 36993_at PDGFRB 2.2 down
32408_s_at HNRPC 2.8 up 33240_at PDZRN3 6.4 down
38292_at HOMER2 2.7 up 36502_at PFTK1 3.1 down
33130_at HOXD1 4.2 up 38120_at PKD2 2.0 down
414_at HOXD10 5.9 up 33452_at PLAT 2.7 down
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443_at HOXD4 2.4 up 41544_at PLK2 6.9 down
36882_at HOXD9 4.0 up 36184_at PLOD1 2.1 down
413_at HOXD9 3.0 up 38653_at PMP22 2.3 down
35704_at HRASLS3 4.1 up 41709_at PPFIBP2 2.5 down
40637_at HSPA8 2.2 up 41470_at PROM1 12.1 down
41536_at ID4 5.9 up 36533_at PTGIS 2.8 down
1456_s_at IFI16 6.0 up 533_g_at PTHR1 3.6 down
359_at IL13RA1 13.2 up 33910_at PTPRD 3.7 down
38488_s_at IL15 10.7 up 37701_at RGS2 4.1 down
41005_at ITGA8 11.8 up 35692_at RIS1 7.9 down
32778_at ITPR1 7.3 up 35803_at RND3 4.6 down
32779_s_at ITPR1 9.6 up 213_at ROR1 16.5 down
755_at ITPR1 6.4 up 35638_at RUNX1T1 6.9 down
41585_at KIAA0746 3.2 up 41644_at SASH1 2.2 down
37837_at KIAA0863 2.2 up 36899_at SATB1 3.3 down
36070_at KIAA1199 29.0 up 38127_at SDC1 2.2 down
37554_at KLK6 148.3 up 40856_at SERPINF1 2.9 down
37131_at KLK8 /// KLK9 2.7 up 36225_s_at SFPQ 3.1 down
40899_at KRT19 6.5 up 32521_at SFRP1 6.7 down
37671_at LAMA4 2.9 up 39608_at SIM2 49.2 down
232_at LAMC1 2.5 up 39577_at SOSTDC1 12.1 down
317_at LGMN 2.1 up 35277_at SPON1 4.0 down
40608_at LOC552889 7.5 up 38800_at STMN2 11.7 down
35017_f_at LOC649864 3.4 up 38786_at SVEP1 3.9 down
39009_at LSM3 2.6 up 40069_at SVIL 2.6 down
38749_at LYPD1 8.6 up 35354_at SYNGR1 2.8 down
183_at MAP2 3.4 up 36452_at SYNPO 3.4 down
36180_s_at MAPKAPK2 2.3 up 40560_at TBX2 8.0 down
32571_at MAT2A 5.7 up 32872_at TCF4 29.9 down
33252_at MCM3 2.5 up 32154_at TFAP2A 10.1 down
981_at MCM4 3.9 up 40084_at TFCP2 3.0 down
39018_at MGST3 3.7 up 1385_at TGFBI 4.1 down
31641_s_at MMP23B /// MMP23A /// LOC652002 3.6 up 35846_at THRA 2.4 down
1854_at MYBL2 5.2 up 39339_at TMEM63A 2.6 down
32790_at NCBP2 3.9 up 36079_at TP53I3 2.4 down
989_at NCK1 2.4 up 38408_at TSPAN7 3.9 down
32078_at NEDD4 2.1 up 38469_at TSPAN8 9.4 down
37574_at NEDD9 3.5 up 35178_at WIF1 53.5 down
33169_at NEO1 2.2 up 31862_at WNT5A 7.6 down
40823_s_at NFATC3 5.0 up 40711_at YTHDC1 3.3 down
1985_s_at NME1 3.8 up 35681_r_at ZFHX1B 2.9 down
39073_at NME1 2.0 up 32588_s_at ZFP36L2 2.5 down
33414_at NOMO1 /// NOMO2 /// NOMO3 5.7 up
1539_at NRAS 3.2 up
39240_at NRXN1 6.1 up
31858_at NUTF2 6.6 up
38332_at P2RX4 2.1 up
1557_at PAK1 2.8 up
38186_g_at PAX2 3.3 up
121_at PAX8 12.1 up
36869_at PAX8 7.9 up
37188_at PCK2 2.2 up
37738_g_at PCMT1 3.8 up
1824_s_at PCNA 8.1 up
37900_at PEX11B 2.1 up
1817_at PFDN5 2.9 up
31488_s_at PGK1 5.9 up
146_at PIK4CB 6.3 up
352_at PITPNA 3.4 up
38869_at PLCH1 3.0 up
39525_at PLEKHB2 2.1 up
39126_at PMF1 2.4 up
32310_f_at PMS2L1 2.3 up
35933_f_at PMS2L3 2.1 up
35621_at PMVK 2.1 up
33726_at POLR2D 2.7 up
1486_at POLR2J 2.0 up
782_at POLR3C 2.2 up
40504_at PON2 4.1 up
34366_g_at PPIE 5.8 up
36538_at PPP1R13B 2.1 up
40867_at PPP2R1A 3.0 up
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922_at PPP2R1A 3.7 up
34325_at PQBP1 3.7 up
39149_at PRCC 3.9 up
122_at PRIM2A 3.1 up
226_at PRKAR1A 2.2 up
116_at PRKAR2A 2.1 up
1810_s_at PRKCD 2.5 up
2012_s_at PRKDC 3.3 up
35752_s_at PROS1 2.1 up
40424_at PROSC 2.1 up
40545_at PROSC 6.2 up
37507_i_at PRPF40A /// LOC642455 3.2 up
825_at PRPF4B 2.1 up
36490_s_at PRPS1 7.7 up
642_s_at PSEN1 2.2 up
1448_at PSMA3 2.0 up
1309_at PSMB3 2.1 up
941_at PSMB6 2.5 up
1313_at PSMB7 2.0 up
592_at PSMC3 2.1 up
39155_at PSMD3 2.5 up
39749_at PSMD4 2.1 up
1312_at PSMD8 2.3 up
32548_at PTGES3 2.5 up
38819_at PTK7 7.4 up
801_at PTPN14 6.3 up
31892_at PTPRM 3.5 up
994_at PTPRM 3.0 up
995_g_at PTPRM 3.4 up
1257_s_at QSCN6 2.2 up
41523_at RAB32 2.3 up
600_at RAB5A 4.6 up
37869_at RAB6IP2 /// LOC653152 3.2 up
1753_s_at RAD23A 8.4 up
35397_at RAD51AP1 2.2 up
1917_at RAF1 7.1 up
38062_at RAPGEF5 2.1 up
40556_at RCN1 3.3 up
1053_at RFC2 2.6 up
653_at RFC5 3.9 up
40696_at RIPK1 3.7 up
32944_at ROBO1 /// LOC642132 4.2 up
1382_at RPA1 4.0 up
33424_at RPN1 2.6 up
32036_i_at RPP14 3.9 up
33229_at RPS6KA3 2.2 up
865_at RPS6KA3 2.7 up
39989_at RRAGB 2.9 up
34674_at S100A1 10.2 up
38138_at S100A11 3.8 up
39712_at S100A13 6.4 up
34265_at SCG5 4.9 up
36099_at SFRS1 2.6 up
35259_s_at SFRS2IP 2.7 up
351_f_at SFRS3 3.4 up
37580_at SH3GL3 2.9 up
2010_at SKP1A 2.5 up
38329_at SLC25A13 5.1 up
41271_at SLC7A8 3.4 up
32174_at SLC9A3R1 5.8 up
37753_at SMARCD1 2.5 up
36583_at SNX1 2.3 up
36216_at SNX4 2.8 up
36155_at SPOCK2 5.4 up
36036_at SPTB 4.4 up
36037_g_at SPTB 2.3 up
1031_at SRPK1 2.2 up
31872_at SS18 2.7 up
38846_at SSBP1 2.1 up
34069_s_at SSX2 /// SS18 6.2 up
289_at STAT3 2.4 up
906_at STAT4 21.5 up
Table W2. (continued )
Probe Set ID Gene Symbol FC Regulation Probe Set ID Gene Symbol FC Regulation
31804_f_at SULT1A1 3.2 up
32317_s_at SULT1A2 /// SULT1A1 /// SULT1A3 /// SULT1A4 /// LOC648394 3.0 up
38426_at TAF11 2.5 up
38223_at TBC1D8 3.5 up
39184_at TCEB2 2.1 up
41267_at TCF25 2.7 up
33989_f_at TEGT 10.4 up
1670_at TFDP1 2.4 up
38311_at TGIF2 2.5 up
32670_at THBS3 2.2 up
32830_g_at TIMM17A 3.4 up
40692_at TLE4 3.2 up
36461_at TMED1 2.6 up
34916_s_at TNFRSF4 2.6 up
37048_at TOMM34 2.1 up
1581_s_at TOP2B 3.5 up
1974_s_at TP53 2.4 up
36936_at TSTA3 2.0 up
38089_at UBAP2L 3.6 up
1660_at UBE2N 2.1 up
38560_at UTP20 /// LOC653877 3.2 up
35784_at VAMP3 2.1 up
33124_at VRK2 2.5 up
607_s_at VWF 5.8 up
1058_at WASF3 2.6 up
40090_at WBSCR22 3.9 up
1500_at WT1 12.7 up
783_at WWP1 3.5 up
34642_at YWHAZ 3.2 up
33209_at YY1 2.0 up
41503_at ZHX2 2.9 up
41621_i_at ZNF266 3.2 up
33650_at
HLA-DRB1 /// HLA-DRB3 /// HLA-DRB4 /// HLA-DRB6 ///
LOC649143 /// LOC651845 /// LOC652479 2.3 up 31497_at
GAGE1 /// GAGE2 /// GAGE8
/// LOC645037 /// LOC645093 2.2 down
Figure W1. Relative mRNA levels of WT1 and IFI16 in Wilms tumor samples.
Figure W2. Western blot analysis after transfecting with WT1 shRNA in biological triplicates.
